Zepbound vs. Qsymia

See how Zepbound and Qsymia compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Zepbound is a once-weekly injection that combines two gut hormone pathways, while Qsymia is a daily pill combining a stimulant and an anticonvulsant.

  • Clinical trials show Zepbound produces greater average weight loss than Qsymia, but Zepbound costs several times more per month without insurance.

  • Qsymia is a controlled substance requiring REMS pharmacy enrollment, while Zepbound carries a boxed warning about thyroid tumor risk seen in animal studies.

Zepbound vs. Qsymia Drug Summary

Zepbound

Zepbound (tirzepatide) is a dual GIP/GLP-1 receptor agonist injected under the skin once a week. It is FDA-approved for chronic weight management in adults with obesity or overweight plus a weight-related condition, and separately for moderate-to-severe obstructive sleep apnea in adults with obesity.

Qsymia

Qsymia combines phentermine, a stimulant appetite suppressant, with topiramate, an anticonvulsant, in a single daily extended-release capsule. It is FDA-approved for chronic weight management in adults with obesity or overweight plus a weight-related condition, and in adolescents 12 and older with obesity.

Zepbound vs. Qsymia Side Effects

Zepbound

Most common
nausea (up to 29%)
diarrhea (up to 23%)
constipation (up to 17%)
vomiting (up to 13%)

Qsymia

Most common
paresthesia (up to 21%)
dry mouth (up to 19%)
constipation (up to 16%)
insomnia (up to 11%)

Zepbound vs. Qsymia Dosage

Zepbound

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 2.5 mg once weekly Weeks 1-4
Maximum dose 15 mg once weekly Week 21 onward
Dose changes 5 increases Every 4 weeks

Qsymia

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 3.75 mg/23 mg once daily Days 1-14
Maximum dose 15 mg/92 mg once daily Week 17 onward
Dose changes 3 increases As tolerated

Zepbound vs. Qsymia Indications

Zepbound

Zepbound is FDA-approved for chronic weight management in adults with obesity, or overweight adults with at least one weight-related condition like high blood pressure or type 2 diabetes. It also has a separate approval for moderate-to-severe obstructive sleep apnea in adults with obesity. Both uses call for pairing the medication with a reduced-calorie diet and more physical activity.

  • Obesity (BMI 30 or higher)

  • Overweight (BMI 27+) plus a weight-related condition

  • Moderate-to-severe obstructive sleep apnea with obesity

  • Used alongside diet and exercise

Qsymia

Qsymia is FDA-approved for chronic weight management in adults with obesity, or overweight adults with at least one weight-related condition. It is also approved for adolescents 12 and older with obesity. Like Zepbound, it is meant to be used along with a reduced-calorie diet and increased physical activity.

  • Obesity (BMI 30 or higher) in adults

  • Overweight (BMI 27+) plus a weight-related condition

  • Obesity in adolescents 12 and older

  • Used alongside diet and exercise

Zepbound vs. Qsymia Pros and Cons

Zepbound

Zepbound produced some of the largest average weight-loss results seen in obesity drug trials, and it is the only medication also approved for obstructive sleep apnea. It requires a weekly self-injection and typically costs far more out of pocket than oral options like Qsymia.

Pros

  • Larger average weight loss than Qsymia in trials

  • Only medication also approved for sleep apnea

  • Dosed just once a week

  • Not a controlled substance

Cons

  • Requires self-injection, not a pill

  • Common GI side effects like nausea and diarrhea

  • Roughly $1,050 to $1,100 per month without insurance

  • Boxed warning for thyroid tumor risk seen in animal studies

Qsymia

Qsymia has been on the market since 2012 and is taken as a daily pill instead of an injection. It tends to produce more modest weight loss than Zepbound and comes with its own restrictions, including REMS pharmacy enrollment and monthly pregnancy testing.

Pros

  • Oral capsule, no injections needed

  • Roughly $200 to $350 per month without insurance

  • Longer track record, approved since 2012

  • Also approved for adolescents 12 and older

Cons

  • Schedule IV controlled substance with abuse potential

  • Requires REMS enrollment and certified pharmacies

  • Not for people with glaucoma or hyperthyroidism

  • More modest average weight loss than Zepbound

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.